Insider Selling: Replimune Group (NASDAQ:REPL) Director Sells $113,360.00 in Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Joseph Slattery sold 5,200 shares of the stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $21.80, for a total transaction of $113,360.00. Following the completion of the sale, the director owned 1,467 shares of the company’s stock, valued at approximately $31,980.60. This represents a 78.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Replimune Group Stock Up 0.9%

Replimune Group stock opened at $21.98 on Friday. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $23.54. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11. The firm’s 50-day simple moving average is $14.63 and its 200 day simple moving average is $9.97.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.24. Equities analysts forecast that Replimune Group, Inc. will post -2.40 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on REPL. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Leerink Partners upped their price objective on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Wolfe Research raised Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. upped their price target on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Replimune Group in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Institutional Trading of Replimune Group

A number of institutional investors have recently added to or reduced their stakes in REPL. Essential Partners LLC increased its position in shares of Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after buying an additional 5,624 shares during the period. Allworth Financial LP purchased a new position in Replimune Group during the second quarter valued at approximately $62,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Replimune Group in the 3rd quarter worth approximately $64,000. Legal & General Group Plc bought a new position in Replimune Group in the 2nd quarter valued at $85,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Replimune Group during the 2nd quarter valued at $115,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.